Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults

NCT01783977 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

143

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: DNA-HIV-PT123 vaccine
BIOLOGICAL: NYVAC-HIV-PT1 vaccine
BIOLOGICAL: NYVAC-HIV-PT4 vaccine
BIOLOGICAL: Placebo for DNA-HIV-PT123 vaccine
BIOLOGICAL: Placebo for NYVAC-HIV-PT1 vaccine
BIOLOGICAL: Placebo for NYVAC-HIV-PT4 vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)